DCF Advisers LLC Invests $615,000 in AnaptysBio, Inc. $ANAB

DCF Advisers LLC acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, Holdings Channel reports. The institutional investor acquired 9,114 shares of the biotechnology company’s stock, valued at approximately $615,000.

Other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC grew its position in AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 18,165 shares in the last quarter. Creative Planning lifted its position in AnaptysBio by 26.9% during the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock worth $374,000 after buying an additional 3,571 shares in the last quarter. JPMorgan Chase & Co. lifted its position in AnaptysBio by 1,631.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock worth $5,497,000 after buying an additional 233,325 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of AnaptysBio during the 2nd quarter worth about $528,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of AnaptysBio during the 2nd quarter worth about $3,348,000.

Wall Street Analyst Weigh In

ANAB has been the subject of several analyst reports. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. UBS Group increased their price target on AnaptysBio from $60.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. HC Wainwright began coverage on AnaptysBio in a research note on Wednesday, June 10th. They issued a “buy” rating and a $95.00 price target for the company. Finally, Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $82.00.

AnaptysBio Price Performance

Shares of ANAB stock opened at $59.26 on Thursday. The stock has a market cap of $1.75 billion, a P/E ratio of -54.87 and a beta of 0.72. The company has a fifty day moving average price of $58.48 and a two-hundred day moving average price of $58.71. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.